What the NICE guidelines say about Mounjaro for diabetes and weight loss

What NICE TA1026 actually says about type 2 diabetes as a qualifying condition

When NICE published its appraisal of tirzepatide for weight management (TA1026, December 2024, updated September 2025), it set the primary BMI threshold at 35 kg/m² with at least one weight-related comorbidity. Type 2 diabetes sits firmly on that list, alongside conditions such as hypertension, dyslipidaemia, obstructive sleep apnoea and cardiovascular disease. So a person with a BMI of 35 and a type 2 diabetes diagnosis meets the comorbidity part of the NICE weight-management criteria.

There is an important nuance about BMI thresholds. For people from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds, the NICE threshold is reduced by 2.5 kg/m², bringing the qualifying BMI to 32.5 rather than 35. A full breakdown of these NICE thresholds sets out exactly how the criteria apply in practice.

What NICE does not do is guarantee NHS access. The NHS England phased rollout means that even people who meet the clinical criteria may not yet be in a cohort that their GP or specialist weight management service is funded to treat. Meeting the NICE criteria is a necessary condition, not a sufficient one, worth keeping in mind if you have been told you qualify but cannot access treatment yet.

The SURMOUNT-2 evidence: what tirzepatide showed in people already living with type 2 diabetes

A question our prescribers hear most weeks is whether Mounjaro works as well for people who already have type 2 diabetes as it does for people without it. The SURMOUNT-2 trial speaks directly to this. It enrolled around 938 adults with obesity and established type 2 diabetes and ran for 72 weeks. At the 15 mg dose, participants lost an average of roughly 15% of their body weight alongside diet and physical activity support, a clinically meaningful reduction in a population where significant weight loss has historically been hard to achieve with medicines alone. The evidence on Mounjaro and type 2 diabetes covers this trial in more detail.

These results also translated into meaningful improvements in HbA1c (a measure of blood-sugar control), which is relevant because many people with type 2 diabetes are looking for a medicine that addresses both weight and glucose. Tirzepatide holds a separate UK licence for glycaemic control in type 2 diabetes, assessed through NICE's technology appraisal for diabetes rather than TA1026. The two licences overlap in the same person but travel through different commissioning routes on the NHS. Understanding which route applies to you requires a conversation with your GP or diabetes specialist. More on how tirzepatide is used specifically in type 2 diabetes explains that distinction.

What remains uncertain, and what your prescriber needs to know

The clinical picture for someone with type 2 diabetes starting tirzepatide is more detailed than for someone without it. Several things that are settled in the weight-management-only population require closer prescriber attention when diabetes is present.

Interactions with existing glucose-lowering medicines matter significantly. Combining tirzepatide with a sulphonylurea or with insulin carries a meaningful risk of hypoglycaemia (low blood sugar); dose adjustments to those existing medicines are usually needed and must be planned by the prescriber before treatment starts. The tirzepatide overview on this site notes the interaction question, but the specifics are for your prescriber and the medicine's Summary of Product Characteristics on the eMC, not a general guide.

Gastrointestinal side effects (nausea, slowed stomach emptying, changes to appetite) are common at initiation and after dose increases. In someone managing blood sugar through diet timing or insulin doses, these effects can disrupt glucose patterns in ways that are hard to predict without clinical oversight. It is not a reason to avoid tirzepatide, and for many people with type 2 diabetes the benefits are substantial, as the Mounjaro PCOS study also illustrates in a related hormonal and metabolic context, but it is a reason to start with prescriber support in place rather than without it.

If you are managing type 1 diabetes, the picture is different again: tirzepatide is not licensed for type 1 diabetes, and that distinction is explained separately. Pregnancy, breastfeeding, and trying to conceive are all situations where tirzepatide is not recommended; anyone in those circumstances should speak to their GP or specialist about alternatives before making any treatment decision.

For people exploring private treatment, speaking to our prescribers is the right starting point. At nume, every consultation is read by a GPhC-registered Independent Prescriber on the same day, a clinician who will take your diabetes history, current medicines and overall health into account before any treatment is considered. Our clinical team is detailed on the clinical team profile page.